ES2108679T3 - Utilizacion de receptores monoclonales frente a oncoproteinas para vigilar terapias contra el cancer. - Google Patents

Utilizacion de receptores monoclonales frente a oncoproteinas para vigilar terapias contra el cancer.

Info

Publication number
ES2108679T3
ES2108679T3 ES88310540T ES88310540T ES2108679T3 ES 2108679 T3 ES2108679 T3 ES 2108679T3 ES 88310540 T ES88310540 T ES 88310540T ES 88310540 T ES88310540 T ES 88310540T ES 2108679 T3 ES2108679 T3 ES 2108679T3
Authority
ES
Spain
Prior art keywords
sample
oncoproteins
pattern
against cancer
therapies against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88310540T
Other languages
English (en)
Inventor
Henry Lee Niman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Original Assignee
Ligand Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceuticals Inc filed Critical Ligand Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2108679T3 publication Critical patent/ES2108679T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

UN METODO DE DIAGNOSIS, POR EJEMPLO, PARA DETECTAR LA PRESENCIA O GRAVEDAD DEL CANCER, INCLUYE PONER EN CONTACTO UNA MUESTRA DEL CUERPO, POR EJEMPLO ORINA, CON DOS MOLECULAS RECEPTORAS DIFERENTES POR LO MENOS, PARA GENERAR UN PRIMER PATRON DE REACTIVIDAD. ESTE PATRON SE PUEDE GENERAR COMO MONOCLONAL QUE ENLAZA A POLIPEPTIDOS EN LA MUESTRA QUE SE CODIFICA POR ENCOGENES, Y LUEGO SE COMPARA CON UN SEGUNDO PATRON DE REACTIVIDAD GENERADO POR UNA MUESTRA BIOLOGICA CONOCIDA. ESTA MUESTRA CONOCIDA ES INDICATIVA DE LA EXPRESION ENCOGENE O SECUENCIAS RELACIONADAS CON ENCOGENES. TAMBIEN SE DESCRIBEN CONJUNTOS PARA DIAGNOSTICO QUE UTILIZAN ESTE METODO, DONDE LOS RESULTADOS SE PUEDEN INTERPRETAR MEDIANTE EXPLORADOR AUTOMATICO.
ES88310540T 1987-11-09 1988-11-09 Utilizacion de receptores monoclonales frente a oncoproteinas para vigilar terapias contra el cancer. Expired - Lifetime ES2108679T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11882387A 1987-11-09 1987-11-09

Publications (1)

Publication Number Publication Date
ES2108679T3 true ES2108679T3 (es) 1998-01-01

Family

ID=22380954

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88310540T Expired - Lifetime ES2108679T3 (es) 1987-11-09 1988-11-09 Utilizacion de receptores monoclonales frente a oncoproteinas para vigilar terapias contra el cancer.

Country Status (10)

Country Link
US (1) US20030215894A1 (es)
EP (1) EP0318179B1 (es)
JP (1) JPH03500928A (es)
AT (1) ATE157172T1 (es)
AU (2) AU2497388A (es)
CA (1) CA1339069C (es)
DE (1) DE3856004T2 (es)
ES (1) ES2108679T3 (es)
GR (1) GR3025378T3 (es)
WO (1) WO1989004489A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733738A (en) * 1983-08-17 1998-03-31 Ligand Pharmaceuticals Polypeptide-induced monoclonal receptors to protein ligands
CA1219232A (en) * 1983-08-17 1987-03-17 Richard A. Lerner Polypeptide-induced monoclonal receptors to protein ligands
AU596670B2 (en) * 1986-05-06 1990-05-10 Amgen, Inc. Assays and antibodies for n-myc proteins
EP0354808B1 (en) * 1988-08-12 1997-12-03 Ligand Pharmaceuticals Incorporated Polypeptide-induced monoclonal receptors to protein ligands
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
US6489451B1 (en) 1997-04-10 2002-12-03 Hefei-Siu-Fung Ustc Pharmaceutical Co., Ltd. Antithrombosis enzyme from the snake venom of agkistrodon acutus
US7098025B1 (en) 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
ATE393912T1 (de) * 1998-02-04 2008-05-15 Invitrogen Corp Microarrays und ihre verwendungen
DE69907155T2 (de) * 1998-02-18 2004-02-05 Theryte Ltd. Krebsbehandlung
HUE039085T2 (hu) 2006-01-20 2018-12-28 Cell Signaling Technology Inc Transzlokáció és mutáns ROS kináz humán nem-kissejtes tüdõ karcinómában
US8383799B2 (en) 2006-01-20 2013-02-26 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535058A (en) * 1982-10-01 1985-08-13 Massachusetts Institute Of Technology Characterization of oncogenes and assays based thereon
US4798787A (en) * 1984-09-19 1989-01-17 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
EP0206065A3 (en) * 1985-06-27 1989-04-19 James R. Feramisco Method of detecting oncogene and proto-oncogene related proteins in extracellular biological fluids

Also Published As

Publication number Publication date
AU2967792A (en) 1993-02-11
EP0318179A2 (en) 1989-05-31
GR3025378T3 (en) 1998-02-27
AU2497388A (en) 1989-05-11
ATE157172T1 (de) 1997-09-15
DE3856004T2 (de) 1997-12-18
AU665591B2 (en) 1996-01-11
JPH03500928A (ja) 1991-02-28
EP0318179B1 (en) 1997-08-20
US20030215894A1 (en) 2003-11-20
EP0318179A3 (en) 1990-08-01
DE3856004D1 (de) 1997-09-25
WO1989004489A1 (en) 1989-05-18
CA1339069C (en) 1997-07-29

Similar Documents

Publication Publication Date Title
ES2108679T3 (es) Utilizacion de receptores monoclonales frente a oncoproteinas para vigilar terapias contra el cancer.
DK0991421T3 (da) Påvisning og modulering af IAP'er og NAIP i forbindelse med diagnose og behandling af proliferativ sygdom
ES8303072A1 (es) Metodo para diagnosticar la presencia de una enfermedad especifica, una etapa especifica de una enfermedad, o mas aler- gia, en un paciente, a base de la deteccion de la reacciones antigeno-anticuerpo en un substrato.
ATE157123T1 (de) Verfahren und vorrichtung zur amperometrischen diagnostischen analyse
ATE246378T1 (de) Verfahren zum feststellen der preparationsgüte von objektträgern und proben
PT914344E (pt) Ensaio e reagentes para a quantificacao de hbnp
SE7906148L (sv) Forfarande for framstellning av en biologisk komposition for anvendning sasom referenskontroll vid diagnostiska tester
ATE76689T1 (de) Verfahren fuer die beschaffung interner referenzen zur verwendung in analyt-rezeptor-tests.
AU9021898A (en) Prostate tumor polynucleotide and antigen compositions
DE58908905D1 (de) Verfahren zur Bestimmung einer spezifisch bindefähigen Substanz.
ATE107776T1 (de) Verfahren zur bestimmung einer spezifisch bindefähigen substanz.
DE3865678D1 (de) Satz und verfahren zur diagnose der iga-nephropathie.
ES2067024T3 (es) Metodo y kit para determinar actividades fosforilantes y desfosforilantes de tirosina.
FR2679252B1 (fr) Systeme de sondes permettant d'effectuer le typage hla dr, et procede de typage utilisant lesdites sondes.
DE69123723T2 (de) Diagnostisches verfahren und reagenz für hiv
ATE181332T1 (de) Vom gtpase-aktivierenden protein (gap) abgeleitete peptide sowie deren diagnostische und therapeutische verwendung
EP0563244A4 (en) Human phospholipase activating protein and methods for diagnosis of rheumatoid arthritis
SE9602234D0 (sv) A novel diagnostic method utilizing ECP, and reagents to be used in the methods
SU608098A1 (ru) Способ определени влагостойкости непровод щих электрический ток материалов
ATE208901T1 (de) Verfahren zum nachweis einer hormon- bzw. antihormonresistenz bei tumoren
ATE208041T1 (de) A-protein als diagnostikum für krebs
ATE118617T1 (de) Enzym-quantifizierungstest auf einem docht.
ES2157426T3 (es) Modulacion de las propiedades de union de coparticipes de union de un acido nucleico.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 318179

Country of ref document: ES